{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:21:48Z","timestamp":1783578108876,"version":"3.55.0"},"reference-count":11,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Budesonide\u2010MMX has an established role in the management of relapsing mild\u2010to\u2010moderate ulcerative colitis. Data regarding effectiveness and tolerability in real\u2010life clinical practice are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>The aim of this study was to assess the use of budesonide\u2010MMX in ulcerative colitis, as well as short\u2010term effectiveness and tolerability in real\u2010life practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study of adult patients with mild\u2010to\u2010moderate ulcerative colitis treated with budesonide\u2010MMX at four tertiary inflammatory bowel disease centres in Italy from June 2016 to February 2018. Demographic and clinical features of patients, the use of budesonide\u2010MMX, disease course and concomitant therapy were recorded. The primary outcome assessed was clinical remission at 2 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 82 patients with active mild\u2010to\u2010moderate ulcerative colitis were included in the study with a mean age of 45.9 years and a median partial Mayo Score of 4 (interquartile range 3\u20135). A total of 41 patients were male. Overall, 36 had extensive colitis, 38 left\u2010sided colitis and eight proctitis. Treatments at the time of inclusion included 10 patients receiving biologic therapy, seven azathioprine and 54 mesalazine or salazopyrin. The main reasons for the addition of budesonide\u2010MMX were clinical relapse (47.5%) or inadequate response to current therapy (39.0%). In total, 50% of patients achieved clinical remission, whereas 9.8% had clinical improvement. No response was noted in 40.2% of subjects. Using multivariate binary logistic regression, a moderate degree of activity was the main independent predictor of non\u2010response. Eight significant adverse effects were reported in six patients with three discontinuing treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In real\u2010life clinical practice, budesonide\u2010MMX is commonly used in combination with other therapies, both for acute disease flares and for partial response to therapy.<\/jats:p><\/jats:sec>","DOI":"10.1177\/2050640619864257","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T05:02:02Z","timestamp":1563426122000},"page":"1164-1170","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["Use, effectiveness and tolerability of budesonide\u2010MMX in ulcerative colitis: A real\u2010life experience"],"prefix":"10.1002","volume":"7","author":[{"given":"Giovanni","family":"Maconi","sequence":"first","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-6362","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Mezzina","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Landi","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Grillo","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit ASST Rhodense Rho Hospital Rho Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bosani","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit General Hospital Legnano Legnano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pastorelli","sequence":"additional","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Dell'Era","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Chibbar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology Beth Isreal Deaconess Medical Centre Boston United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Carmagnola","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Molteni","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cassinotti","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Massari","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Ardizzone","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit University of Milan Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11]]},"reference":[{"key":"e_1_2_12_2_2","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current Management","volume":"11","author":"Harbord M","year":"2017","journal-title":"J Crohns Colitis"},{"key":"e_1_2_12_3_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1442432"},{"key":"e_1_2_12_4_2","article-title":"Budesonide multi-matrix is efficacious for mesalamine-refractory, mild to moderate ulcerative colitis: A randomized, placebo-controlled trial","volume":"11","author":"Rubin DT","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"10","key":"e_1_2_12_5_2","first-page":"CD007698","article-title":"Oral budesonide for induction of remission in ulcerative colitis","volume":"26","author":"Sherlock ME","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_12_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13076"},{"issue":"5","key":"e_1_2_12_7_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study","volume":"143","author":"Sandborn WJ","year":"2012","journal-title":"Gastroenterol"},{"key":"e_1_2_12_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304258"},{"key":"e_1_2_12_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20520"},{"issue":"13","key":"e_1_2_12_10_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1471-230X-13-23","article-title":"Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database","volume":"30","author":"Lachaine J","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"e_1_2_12_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2017.1256200"},{"key":"e_1_2_12_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001201"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619864257","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640619864257","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619864257","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T11:12:42Z","timestamp":1693739562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640619864257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":11,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.1177\/2050640619864257"],"URL":"https:\/\/doi.org\/10.1177\/2050640619864257","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}